LifeMD Securities Suit Advances as Lead-Plaintiff Deadlines Near

The complaint claims the company boosted its 2025 outlook despite mounting RexMD acquisition costs alongside refund pressures in virtual weight care.

Overview

The federal class action, captioned Johnston v. LifeMD, Inc., was filed in the Eastern District of New York and targets statements within the May 7–August 5, 2025 class period.
Plaintiff firms set competing lead-plaintiff deadlines, with Levi & Korsinsky citing October 25, 2025 and Hagens Berman and Faruqi & Faruqi pointing to October 27, 2025.
Filings assert LifeMD overstated its competitive position and failed to disclose rising customer-acquisition costs in RexMD plus higher-than-expected refunds in weight-management programs tied to GLP-1 drugs.
On August 5, 2025 the company missed Q2 estimates and cut full-year guidance, later attributing performance to temporary elevated acquisition costs and refund issues, and the stock fell about 44% the next day.
Law firms are soliciting investors and whistleblowers, and the case remains at an early stage with allegations unproven and no class yet certified.